<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7443335\results\search\disease\results.xml">
  <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
  <result pre="COVID-19 resource centre remains active. Abstract The recent corona virus" exact="disease" post="(COVID-19) outbreak has claimed the lives of many around"/>
  <result pre="strategies to prevent, treat and eradicate the virus. COVID-19, an" exact="infectious disease" post="caused by a novel corona virus and no approved"/>
  <result pre="to prevent, treat and eradicate the virus. COVID-19, an infectious" exact="disease" post="caused by a novel corona virus and no approved"/>
  <result pre="prevention and pathophysiology of COVID-19 â€¢Current treatment options for COVID-19" exact="disease" post="â€¢Nanotechnology approaches to aid in the development of COVID-19"/>
  <result pre="â€¢Current state of knowledge and research priorities regarding the pandemic" exact="disease" post="â€¢Complications, lessons learned, immunity, financial loss and preparedness associated"/>
  <result pre="2019, the World Health Organization (WHO) was informed about the" exact="pneumonia" post="case of unknown cause, detected in the seafood market"/>
  <result pre="coronavirus (n-CoV) based on the laboratory findings in reference to" exact="Severe" post="Acute Respiratory Syndrome (SARS) and Middle East respiratory syndrome"/>
  <result pre="(n-CoV) based on the laboratory findings in reference to Severe" exact="Acute" post="Respiratory Syndrome (SARS) and Middle East respiratory syndrome coronavirus"/>
  <result pre="based on the laboratory findings in reference to Severe Acute" exact="Respiratory" post="Syndrome (SARS) and Middle East respiratory syndrome coronavirus (MERS)."/>
  <result pre="on the laboratory findings in reference to Severe Acute Respiratory" exact="Syndrome" post="(SARS) and Middle East respiratory syndrome coronavirus (MERS). In"/>
  <result pre="reference to Severe Acute Respiratory Syndrome (SARS) and Middle East" exact="respiratory" post="syndrome coronavirus (MERS). In a short span of time,"/>
  <result pre="to Severe Acute Respiratory Syndrome (SARS) and Middle East respiratory" exact="syndrome" post="coronavirus (MERS). In a short span of time, it"/>
  <result pre="(SARS) and Middle East respiratory syndrome coronavirus (MERS). In a" exact="short" post="span of time, it has become a global phenomenon"/>
  <result pre="has become a global phenomenon since the case of single" exact="pneumonia" post="in Wuhan. Later, on 30 January 2020, WHO declared"/>
  <result pre="stages globally. The first stage, is when cases of an" exact="infection" post="are imported into a country from the other infectious"/>
  <result pre="an infection are imported into a country from the other" exact="infectious" post="country. The second stage of an outbreak is when"/>
  <result pre="stage of an outbreak and fourth stage is when an" exact="infection" post="becomes endemic with no clear endpoint. The world has"/>
  <result pre="reported to WHO. Transmission was primarily person to person through" exact="infectious" post="droplets that occurred during coughing or sneezing, through personal"/>
  <result pre="have originated from bats and transmitted to humans from an" exact="intermediate" post="host, civets and dromedary camels, respectively. For SARS-CoV-2, the"/>
  <result pre="and dromedary camels, respectively. For SARS-CoV-2, the zoonotic source and" exact="intermediate" post="host is not confirmed yet and research is going"/>
  <result pre="19Â days, making it even more challenging to screen the" exact="infection" post="[3]. The care advised is to give fluid management,"/>
  <result pre="management, oxygen supportive as patients condition [4,5] and antibiotic in" exact="secondary" post="infection if any reported [6]. Based on evidence from"/>
  <result pre="oxygen supportive as patients condition [4,5] and antibiotic in secondary" exact="infection" post="if any reported [6]. Based on evidence from laboratory,"/>
  <result pre="protein (S). In which, M determines the shape of the" exact="viral" post="envelope and forms the central organizer of n-CoV assembly."/>
  <result pre="viral envelope and forms the central organizer of n-CoV assembly." exact="Protein" post="E interacts with M protein to form the viral"/>
  <result pre="assembly. Protein E interacts with M protein to form the" exact="viral" post="envelope. The crown like appearance of the n-CoV is"/>
  <result pre="virus envelope. The S protein is a critical determinant of" exact="viral" post="host range, tissue tropism and a major inducer of"/>
  <result pre="COVID-19are varying from asymptomatic forms to clinical conditions characterized by" exact="respiratory" post="failure to multi-organ and systemic manifestations [11].The most common"/>
  <result pre="to clinical conditions characterized by respiratory failure to multi-organ and" exact="systemic" post="manifestations [11].The most common symptoms include fever, cough, and"/>
  <result pre="other symptoms include sputum production, headache, haemoptysis, diarrhea, dyspnoea, and" exact="lymphopenia" post="[12]. The clinical manifestations of the disease were divided"/>
  <result pre="diarrhea, dyspnoea, and lymphopenia [12]. The clinical manifestations of the" exact="disease" post="were divided into three categories by authors of Chinese"/>
  <result pre="three categories by authors of Chinese CDC report. First, mild" exact="pneumonia" post="and non-pneumonia are in mild category (81% of cases)."/>
  <result pre="blood pressure of the oxygen (partial pressure of oxygen, PaO2)," exact="respiratory" post="frequencyÂ â‰¥Â 30/min, and the percentage of oxygen supplied"/>
  <result pre="oxygen, FiO2)]Â 50% within 24 to 48Â h in severe" exact="disease" post="category in approximately 14% of cases, and third respiratory"/>
  <result pre="severe disease category in approximately 14% of cases, and third" exact="respiratory" post="failure, septic shock, and/or multiple organ dysfunction or failure"/>
  <result pre="category in approximately 14% of cases, and third respiratory failure," exact="septic shock," post="and/or multiple organ dysfunction or failure in critical condition,"/>
  <result pre="important diagnostic tools to diagnose COVID-19.Clinical features revealed by a" exact="chest" post="CT scan presented as pneumonia, however, there were abnormal"/>
  <result pre="as pneumonia, however, there were abnormal features such as RNAaemia," exact="acute" post="respiratory distress syndrome, acute cardiac injury, and incidence of"/>
  <result pre="pneumonia, however, there were abnormal features such as RNAaemia, acute" exact="respiratory" post="distress syndrome, acute cardiac injury, and incidence of grand-glass"/>
  <result pre="were abnormal features such as RNAaemia, acute respiratory distress syndrome," exact="acute" post="cardiac injury, and incidence of grand-glass opacities that led"/>
  <result pre="transmission is thought to occur through near contacts mainly through" exact="respiratory" post="droplets produced during coughing or sneezing by an infected"/>
  <result pre="transmissibility of a virus, representing the average number of new" exact="infections" post="generated by an infectious person in a fully susceptible"/>
  <result pre="representing the average number of new infections generated by an" exact="infectious" post="person in a fully susceptible population. Therefore, R0 can"/>
  <result pre="remains unstable during the initial stages of pandemic due to" exact="short" post="onset time and insufficient data availability. 6 Prevention of"/>
  <result pre="Prevention is always better than cure to combat of any" exact="infectious disease." post="To fight the unprecedented and rapidly progressing COVID-19, the"/>
  <result pre="public awareness should be created regarding the unusual symptoms like" exact="chronic" post="cough or shortness of breath. Quarantine of suspected people,"/>
  <result pre="social gatherings, temporary school closure, home isolation, close monitoring of" exact="symptomatic" post="individual, provision of life supports (e.g. oxygen supply, mechanical"/>
  <result pre="transmissions of SARS-CoV. ACE-2 protein is abundantly found in alveolar" exact="epithelial" post="cells of lungs and enterocytes of small intestine. It"/>
  <result pre="enterocytes of small intestine. It was found that the virus" exact="primary" post="binds to the target site on lung epithelial cells."/>
  <result pre="the virus primary binds to the target site on lung" exact="epithelial" post="cells. Wang et al also found that ACE-2 was"/>
  <result pre="SARS-CoV-2 infection, which may help to understand the routes of" exact="infection" post="and disease manifestations [32]. However, patients with SARS-CoV-2 infection"/>
  <result pre="which may help to understand the routes of infection and" exact="disease" post="manifestations [32]. However, patients with SARS-CoV-2 infection primarily exhibit"/>
  <result pre="of infection and disease manifestations [32]. However, patients with SARS-CoV-2" exact="infection" post="primarily exhibit lesions in the lungs, despite the ACE-2"/>
  <result pre="be investigated further. In addition, ACE-2 is highly expressed in" exact="vascular" post="endothelial cells, which raises the question of whether the"/>
  <result pre="the question of whether the virus can cause damage to" exact="vascular" post="endothelial cells or impact glomerular function. Xu et al."/>
  <result pre="et al. recently found that it has been seen rare" exact="kidney damage" post="in COVID-19 patients in Zhejiang [33]. It is not"/>
  <result pre="clinical studies, which raises the question of whether novel coronavirus" exact="infection" post="causes more deaths by multiple organ dysfunction syndrome (MODS)"/>
  <result pre="novel coronavirus infection causes more deaths by multiple organ dysfunction" exact="syndrome" post="(MODS) or respiratory failure [31]. SARS-CoV-2 spike (S) glycoprotein"/>
  <result pre="causes more deaths by multiple organ dysfunction syndrome (MODS) or" exact="respiratory" post="failure [31]. SARS-CoV-2 spike (S) glycoprotein binds with ACE-2"/>
  <result pre="on a large number of cells and tissues. Levels of" exact="tumor" post="necrosis factor Î± (TNF-Î±), IL-1Î², IL-8, IL-12, monocyte chemoattractant"/>
  <result pre="Levels of tumor necrosis factor Î± (TNF-Î±), IL-1Î², IL-8, IL-12," exact="monocyte" post="chemoattractant protein 1 (MCP1), macrophage inflammatory protein 1A (MIP1A)and"/>
  <result pre="shown in Fig. 2 [30]. The incidence of ARDS, shock," exact="secondary" post="infection, acute kidney injury and heart was significantly higher"/>
  <result pre="Fig. 2 [30]. The incidence of ARDS, shock, secondary infection," exact="acute" post="kidney injury and heart was significantly higher in patients"/>
  <result pre="2 [30]. The incidence of ARDS, shock, secondary infection, acute" exact="kidney injury" post="and heart was significantly higher in patients with intensive"/>
  <result pre="The incidence of ARDS, shock, secondary infection, acute kidney injury" exact="and heart" post="was significantly higher in patients with intensive care unit"/>
  <result pre="incidence of ARDS, shock, secondary infection, acute kidney injury and" exact="heart" post="was significantly higher in patients with intensive care unit"/>
  <result pre="above normal was significantly higher than that in the patients." exact="Infection" post="with MERS coronavirus can induce increased concentration of pro-inflammatory"/>
  <result pre="benefit from IL-6 pathway inhibition given the associated Cytokine Release" exact="Syndrome" post="(CRS) and sHLH (Secondary hemophagocytic lymphohistiocytosis) like serum cytokine"/>
  <result pre="death. Wan et al. found that CD4+T and CD8+T were" exact="lower" post="in severe patients, which suggested that lymphocytes were more"/>
  <result pre="which suggested that lymphocytes were more inhibited in severe patients." exact="Lymphocytopenia" post="may be related to a cytokine storm caused by"/>
  <result pre="Lymphocytopenia may be related to a cytokine storm caused by" exact="viral" post="invasion. In mild patient, reduction rate of CD4+T, CD8+T,"/>
  <result pre="antibodies, and vaccines have rapidly emerged. These all treatment is" exact="symptomatic" post="but oxygen therapy using ventilator plays major role in"/>
  <result pre="drug treatment by WHO, plasma therapy. 9 Mechanical ventilation When" exact="respiratory" post="failure is occurred in COVID-19 patients, mechanical ventilation becomes"/>
  <result pre="treatment. In addition, hemodynamic support is also required for managing" exact="septic shock." post="Mechanical ventilation should be with lower tidal volumes (4"/>
  <result pre="required for managing septic shock. Mechanical ventilation should be with" exact="lower" post="tidal volumes (4 to 6Â ml/kg predicted body weight;"/>
  <result pre="volumes (4 to 6Â ml/kg predicted body weight; PBW) and" exact="lower" post="inspiratory pressures, reaching a plateau pressure (Pplat)Â 2O [38]."/>
  <result pre="combination of drugs serves as an effective treatment against COVID-19." exact="Systemic" post="corticosteroids (Hydrocortisone, methyl prednisolone, dexamethasone, and prednisolone) are not"/>
  <result pre="dexamethasone, and prednisolone) are not recommended in the treatment of" exact="viral pneumonia" post="or ARDS due to the increased mortality and secondary"/>
  <result pre="and prednisolone) are not recommended in the treatment of viral" exact="pneumonia" post="or ARDS due to the increased mortality and secondary"/>
  <result pre="viral pneumonia or ARDS due to the increased mortality and" exact="secondary" post="infection rates in influenza, impaired clearance of SARS-CoV and"/>
  <result pre="pneumonia or ARDS due to the increased mortality and secondary" exact="infection" post="rates in influenza, impaired clearance of SARS-CoV and MERS-CoV,"/>
  <result pre="of corticosteroid therapy in survivors [39]. Moreover, COVID-19 is a" exact="viral" post="disease not bacterial infection. Therefore, one should avoid in-appropriate"/>
  <result pre="corticosteroid therapy in survivors [39]. Moreover, COVID-19 is a viral" exact="disease" post="not bacterial infection. Therefore, one should avoid in-appropriate administration"/>
  <result pre="in survivors [39]. Moreover, COVID-19 is a viral disease not" exact="bacterial infection." post="Therefore, one should avoid in-appropriate administration of antibiotics, although"/>
  <result pre="replication, Remdesivir is identified as potent inhibitor in bronchial airway" exact="epithelial" post="and human nasal cells. Administration of early remdesivir was"/>
  <result pre="in a non-lethal rhesus macaque model of SARS-CoV-2 infection, (reduced" exact="pulmonary" post="infiltrates and virus titres in broncho-alveolar lavages vs. vehicle"/>
  <result pre="found that those treated with FPV appeared to have faster" exact="viral" post="clearance and better chest imaging change than patients treated"/>
  <result pre="with FPV appeared to have faster viral clearance and better" exact="chest" post="imaging change than patients treated with LPV/RTV [42]. Chang"/>
  <result pre="out studies on COVID-19 patients by giving favipiravir versus Arbidol." exact="Total" post="240 patients were taken. Among them, 120 patients were"/>
  <result pre="broad-spectrum guanosine analogue against RNA and DNA viruses such as" exact="hepatitis C" post="and E [45]. Ribavirin in conjunction with interferon showed"/>
  <result pre="study. This result suggested that ribavirin elicits antiviral activity at" exact="lower" post="concentration with interferon. Therefore, a combination therapy of interferon"/>
  <result pre="drugs is not recommended and patient symptoms will recover after" exact="drug withdrawal." post="Antiviral drugs should be stopped if nucleic acid test"/>
  <result pre="Chloroquine and hydroxychloroquine (HC) had received intense attention because of" exact="viral" post="enzymes or processes inhibition especially in Iran, U.K, France."/>
  <result pre="than 7Â days. The main concerns in rare cases are" exact="cardiac arrest," post="retinal damage and ocular toxicity, particularly due to the"/>
  <result pre="concerns in rare cases are cardiac arrest, retinal damage and" exact="ocular" post="toxicity, particularly due to the fact that, people with"/>
  <result pre="ocular toxicity, particularly due to the fact that, people with" exact="heart" post="conditions are at higher risk of severity [48]. Philippe"/>
  <result pre="found that patients treated with hydroxychloroquine showed significant reduction in" exact="viral infection" post="as compared to the control. Hydroxychloroquine in combination with"/>
  <result pre="that patients treated with hydroxychloroquine showed significant reduction in viral" exact="infection" post="as compared to the control. Hydroxychloroquine in combination with"/>
  <result pre="hydroxychloroquine in COVID-19 patients. This study was carried out on" exact="total" post="368 patients and it was divided in three groups"/>
  <result pre="without HC treatments and combination treatments of HC and azithromycin." exact="Primary" post="outcome of this study was analysis of mortality rate"/>
  <result pre="after combinational treatments when compared to other two groups [50]." exact="Atypical" post="gastrointestinal, cardiovascular manifestations may be present in conjunction with"/>
  <result pre="treatments when compared to other two groups [50]. Atypical gastrointestinal," exact="cardiovascular" post="manifestations may be present in conjunction with constitutional and"/>
  <result pre="cardiovascular manifestations may be present in conjunction with constitutional and" exact="respiratory" post="symptoms in COVID âˆ’19 patients. Akshay Avula et al."/>
  <result pre="Avula et al. identified four patients with radiographic confirmation of" exact="acute" post="stroke and PCR (polymerase chain reaction) confirmed SARS-CoV-2 infection"/>
  <result pre="et al. identified four patients with radiographic confirmation of acute" exact="stroke" post="and PCR (polymerase chain reaction) confirmed SARS-CoV-2 infection and"/>
  <result pre="of acute stroke and PCR (polymerase chain reaction) confirmed SARS-CoV-2" exact="infection" post="and elucidated the imaging findings, clinical characteristics, and the"/>
  <result pre="characteristics, and the clinical course. Average time of onset of" exact="stroke" post="after COVID-19 diagnosis was 12Â days. Elevated levels of"/>
  <result pre="of onset of stroke after COVID-19 diagnosis was 12Â days." exact="Elevated" post="levels of D-dimer, C-reactive protein, ferritin, and interleukin-6 indicating"/>
  <result pre="cascade, respectively, might play a role in the pathophysiology of" exact="stroke" post="in the setting of COVID-19 infection. Despite these reports,"/>
  <result pre="Despite these reports, all four cases here presented with a" exact="cerebrovascular accident" post="in early stages of their illness [51]. The management"/>
  <result pre="in early stages of their illness [51]. The management of" exact="venous thromboembolism" post="(VTE) and antithrombotic therapy for acute coronary syndromes (ACS)"/>
  <result pre="The management of venous thromboembolism (VTE) and antithrombotic therapy for" exact="acute" post="coronary syndromes (ACS) is very crucial in covid-19 pandemic."/>
  <result pre="reduces the cytokine storm in the airway pathways and provides" exact="symptomatic" post="relief to patients from COVID-19 [53]. In a recent"/>
  <result pre="for Health Research (NIHR), the trial is led with 10.13039/100009033NHS" exact="Blood" post="and Transplant and 10.13039/501100000735University of Cambridge experts [55]. The"/>
  <result pre="COVID-19 patients in future. If the treatment will become effective," exact="total" post="10,000Â units of convalescent plasma will be supplied to"/>
  <result pre="shown safe, clinically effective, and reduces mortality based on the" exact="limited" post="scientific data. In this simple method, doctors isolate antibodies"/>
  <result pre="COVID-19 has non-specific treatment. In humans, COVID-19 kicks off the" exact="respiratory" post="system through droplets from coughs and sneezes of infected"/>
  <result pre="through droplets from coughs and sneezes of infected persons. Generally," exact="respiratory" post="system can be divided into two regions namely upper"/>
  <result pre="Generally, respiratory system can be divided into two regions namely" exact="upper" post="(nasal cavity, sinuses, nasopharynx, oropharynx, larynx, and trachea) and"/>
  <result pre="upper (nasal cavity, sinuses, nasopharynx, oropharynx, larynx, and trachea) and" exact="lower" post="tract (bronchioles, alveolar ducts and alveolar sacs).Their journey to"/>
  <result pre="tract (bronchioles, alveolar ducts and alveolar sacs).Their journey to the" exact="lower" post="respiratory tract after infecting the upper respiratory tract is"/>
  <result pre="(bronchioles, alveolar ducts and alveolar sacs).Their journey to the lower" exact="respiratory" post="tract after infecting the upper respiratory tract is the"/>
  <result pre="sacs).Their journey to the lower respiratory tract after infecting the" exact="upper" post="respiratory tract is the cause of respiratory illness [58]."/>
  <result pre="journey to the lower respiratory tract after infecting the upper" exact="respiratory" post="tract is the cause of respiratory illness [58]. Major"/>
  <result pre="after infecting the upper respiratory tract is the cause of" exact="respiratory" post="illness [58]. Major obstacles in drug delivery to upper"/>
  <result pre="of respiratory illness [58]. Major obstacles in drug delivery to" exact="upper" post="respiratory tract are smaller surface area, lower blood flow,"/>
  <result pre="respiratory illness [58]. Major obstacles in drug delivery to upper" exact="respiratory" post="tract are smaller surface area, lower blood flow, mucus"/>
  <result pre="drug delivery to upper respiratory tract are smaller surface area," exact="lower" post="blood flow, mucus layer (traps inhaled substances) and filtration"/>
  <result pre="foreign objects [59]. The large surface area, ciliated cells of" exact="lower" post="respiratory tract may be ideal area for delivery as"/>
  <result pre="objects [59]. The large surface area, ciliated cells of lower" exact="respiratory" post="tract may be ideal area for delivery as it"/>
  <result pre="ideal area for delivery as it is connected directly to" exact="systemic" post="circulation via pulmonary circulation with few challenges like branched"/>
  <result pre="delivery as it is connected directly to systemic circulation via" exact="pulmonary" post="circulation with few challenges like branched nature alveolar macrophages"/>
  <result pre="circulation with few challenges like branched nature alveolar macrophages and" exact="pulmonary" post="surfactant (phospholipids, proteins and mucins) decrease delivery efficiencies [60]."/>
  <result pre="and mucins) decrease delivery efficiencies [60]. However, the delivery to" exact="lower" post="tract should overcome muco-ciliary and cough clearance mechanisms. To"/>
  <result pre="Î¼m could escape the mucociliary clearance and deposit in the" exact="lower" post="airways. This aerodynamic size range is mainly using in"/>
  <result pre="Interferon-Î±2 are currently available inhaled anti-viral agents against the human" exact="respiratory" post="viruses RSV, rhinovirus, influenza A and B, parainfluenza, adenovirus"/>
  <result pre="Initiative [63]. The principal mechanisms of particle deposition in the" exact="respiratory" post="tract depend on particle size; for larger particles, impaction"/>
  <result pre="range of advantages such as (i) the small size and" exact="morphology" post="of the nanoparticles (NP) enables the drug delivery to"/>
  <result pre="Garcia-Contreras et al. formulated large porous particles for treatments of" exact="tuberculosis" post="in guinea-pig model [69]. Like COVID-19, in tuberculosis disease"/>
  <result pre="treatments of tuberculosis in guinea-pig model [69]. Like COVID-19, in" exact="tuberculosis" post="disease also requires to reach the drug at lung"/>
  <result pre="of tuberculosis in guinea-pig model [69]. Like COVID-19, in tuberculosis" exact="disease" post="also requires to reach the drug at lung site."/>
  <result pre="at lung site. It was observed that treatments of lung" exact="infection" post="using large porous particle significantly reduced bacterial burden as"/>
  <result pre="treatments of lung infection using large porous particle significantly reduced" exact="bacterial" post="burden as compared to other drug delivery. Ben-jebria et"/>
  <result pre="as compared to other drug delivery. Ben-jebria et al. formulated" exact="pulmonary" post="aerosol drug delivery for porous microparticles. It was found"/>
  <result pre="porous microparticles. It was found that particles deposit inside the" exact="lower" post="lungs was increased as compared to conventional dosage form."/>
  <result pre="lungs was increased as compared to conventional dosage form. The" exact="systemic" post="bioavailability by pulmonary route was increased using porous microparticles"/>
  <result pre="as compared to conventional dosage form. The systemic bioavailability by" exact="pulmonary" post="route was increased using porous microparticles [70]. It was"/>
  <result pre="effect and deep lung deposition, cisplatin microcrystals were prepared by" exact="high pressure" post="homogenization (HPH) in isopropanol (IPA) then embedded into solubilized"/>
  <result pre="surface tension of particles thus facilitating particle migration deeply to" exact="peripheral" post="regions of lungs. Moreover, PEGylation using muco-penetrating DPPE-PEG provided"/>
  <result pre="the lungs [71]. In COVID-19 infection, drug has to reach" exact="lower" post="respiratory tract. Santo et al. formulated dry powder of"/>
  <result pre="lungs [71]. In COVID-19 infection, drug has to reach lower" exact="respiratory" post="tract. Santo et al. formulated dry powder of quercetin"/>
  <result pre="Silver nanoparticles (AgNP) are widely researched nanotechnology approach to treat" exact="viral" post="infections. Many assumptions of NP have already been made"/>
  <result pre="may not be similar in all viruses. For example, the" exact="viral" post="inhibition in HSV-2 is achieved due to binding of"/>
  <result pre="to sulfhydryl group of surface glycoproteins of virus which prevent" exact="viral" post="internalization. In virus like Peste des petits ruminants, AgNP"/>
  <result pre="AgNP interacts with virion surface and core protein to impair" exact="viral" post="entry into target cells [76]. The virucidal activity of"/>
  <result pre="7Â nm can be highly effective to prevent and treat" exact="viral infection" post="at initial stage of respiratory infections [77]. Sarkar has"/>
  <result pre="nm can be highly effective to prevent and treat viral" exact="infection" post="at initial stage of respiratory infections [77]. Sarkar has"/>
  <result pre="to prevent and treat viral infection at initial stage of" exact="respiratory" post="infections [77]. Sarkar has hypothesized that the application of"/>
  <result pre="prevent and treat viral infection at initial stage of respiratory" exact="infections" post="[77]. Sarkar has hypothesized that the application of water"/>
  <result pre="anti-viral agent against HIV-1, H1N1, H3N2, H5N1, dengue virus, bovine" exact="viral" post="diarrhea virus and Foot-and-mouth disease virus [74]. Other metallic"/>
  <result pre="agent against HIV-1, H1N1, H3N2, H5N1, dengue virus, bovine viral" exact="diarrhea" post="virus and Foot-and-mouth disease virus [74]. Other metallic NP"/>
  <result pre="H3N2, H5N1, dengue virus, bovine viral diarrhea virus and Foot-and-mouth" exact="disease" post="virus [74]. Other metallic NP like Magnetic, Titanium, and"/>
  <result pre="advantages but their applications in the field of virology are" exact="limited" post="to some viruses. Antiviral or virucidal activities of these"/>
  <result pre="carbon-based nanomaterials have been evaluated against some viruses such as" exact="herpes" post="simplex virus type 1(HIV-1) [79], H3N2 [80], Grass carp"/>
  <result pre="type 1(HIV-1) [79], H3N2 [80], Grass carp reovirus (GCRV) [81]and" exact="Respiratory" post="syncytial virus (RSV) [82]. Fullerenes are formed by 60"/>
  <result pre="insoluble, but derivatization makes them water soluble.C60 spontaneously forms a" exact="stable" post="aggregate in contact with water with nanoscale dimensions (25â€&quot;500Â"/>
  <result pre="fullerene monoadducts and tested for antiviral activity in an experimental" exact="infection" post="assay using Ebola virus glycoprotein pseudotyped viral particles on"/>
  <result pre="in an experimental infection assay using Ebola virus glycoprotein pseudotyped" exact="viral" post="particles on Jurkat cells over expressing DC-SIGN and an"/>
  <result pre="effect. Authors explored the nature of CoV, as they are" exact="labile" post="to acidic environment and high temperature [90]. These characteristics"/>
  <result pre="utilized either as therapeutics or for in vitro diagnosis of" exact="viral" post="pathogens. Much progress has been made in the evaluation"/>
  <result pre="has been made in the evaluation of carbon-based nano-systems against" exact="viral infection," post="but their commercialization depends on the safety and superiority"/>
  <result pre="variety of modalities, sizes, surface functionalization, shapes, and compositions [75]." exact="Multiple" post="forms of ONP are being exploited in nanomedicine but"/>
  <result pre="investigated only for some pathogenic viruses like influenza, HIV and" exact="rabies" post="virus [74]. As an alternative to synthetic polymers, some"/>
  <result pre="other examples, which showed promising results as intranasal vaccines against" exact="viral" post="infections. Chitosan is attracted particular interest for intranasal administration"/>
  <result pre="is attracted particular interest for intranasal administration due to their" exact="non-toxic" post="nature, biocompatibility, biodegradability, capability to open up tight junctions"/>
  <result pre="nature, biocompatibility, biodegradability, capability to open up tight junctions between" exact="epithelial" post="cells [100] and ability to be easily modified into"/>
  <result pre="Some other polymers e.g. sodium hyaluronate (HYA) are utilized for" exact="pulmonary" post="drug delivery based on their targeting potential in lungs"/>
  <result pre="in lungs [103]. HYA played a vital role in controlling" exact="tumor" post="proliferation and metastasis via targeting CD-44 receptors [104]. Dendrimers"/>
  <result pre="HYA played a vital role in controlling tumor proliferation and" exact="metastasis" post="via targeting CD-44 receptors [104]. Dendrimers NP are three-dimensional"/>
  <result pre="potential utilization of dendrimers NP in various therapies against tumors," exact="bacterial" post="and viral infections. Dendrimers act as extraordinary vehicle for"/>
  <result pre="of dendrimers NP in various therapies against tumors, bacterial and" exact="viral" post="infections. Dendrimers act as extraordinary vehicle for the targeted"/>
  <result pre="targeted delivery of drug/ gene/ peptides in biological system with" exact="limited" post="utility and application in antiviral therapy [106]. The globular"/>
  <result pre="a promising approach for anti-viral drug delivery for use in" exact="HIV/AIDS" post="therapy [108]. Nanoviricides are polymeric micelles designed by NanoViricides"/>
  <result pre="virus particles and dismantle the virus particle and attack the" exact="viral" post="genome optionally to destroy virus completely. Nanoviricides complete the"/>
  <result pre="attack the viral genome optionally to destroy virus completely. Nanoviricides" exact="complete" post="the task of destroying the virus particles without immune"/>
  <result pre="role in research and development during outbreaks. To combat any" exact="disease" post="the first step in the path of research lies"/>
  <result pre="modification of clinical skill for the rapid diagnosis of the" exact="infection" post="and tracks the changes in virulence. Newly emerged virus"/>
  <result pre="from animals to humans remains unclear; it may involve other/" exact="intermediate" post="hosts as seen with SARS-CoV or MERS-CoV. Finally, the"/>
  <result pre="but elsewhere, with the market serving as a location for" exact="viral" post="contamination and further exposure of humans. The reproductive number"/>
  <result pre="the dynamics of transmission. The importance, impact and existence of" exact="symptomatic" post="and asymptomatic transmission need to be understood clearly along"/>
  <result pre="the area of epidemiology. The need to determine asymptomatic or" exact="symptomatic" post="transmission of COVID âˆ’19, across the range of severity"/>
  <result pre="studies identified patients with other medical conditions such as diabetes," exact="hypertension" post="and cardiovascular disease had more severe infections, and the"/>
  <result pre="patients with other medical conditions such as diabetes, hypertension and" exact="cardiovascular disease" post="had more severe infections, and the disease was more"/>
  <result pre="with other medical conditions such as diabetes, hypertension and cardiovascular" exact="disease" post="had more severe infections, and the disease was more"/>
  <result pre="hypertension and cardiovascular disease had more severe infections, and the" exact="disease" post="was more common in men. Very few cases have"/>
  <result pre="cases have been reported in children [11]. There is currently" exact="limited" post="understanding of severity in different populations and risk groups."/>
  <result pre="innate immune responses work together in sequence to combat any" exact="viral infection" post="in healthy immune cells. In case of defective immune"/>
  <result pre="immune responses work together in sequence to combat any viral" exact="infection" post="in healthy immune cells. In case of defective immune"/>
  <result pre="healthy versus dysfunctional outcomes is required to combat COVID-19. 20" exact="Viral" post="therapeutics in combating COVID-19 Viral therapeutics to fight COVID-19"/>
  <result pre="required to combat COVID-19. 20 Viral therapeutics in combating COVID-19" exact="Viral" post="therapeutics to fight COVID-19 includes monoclonal antibodies, repurposed drugs"/>
  <result pre="for the treatment option. The research in the field of" exact="viral" post="therapeutics should involve identification of more therapeutics candidates for"/>
  <result pre="(R&amp;amp;D) of COVID-19, animal models that can mimic the human" exact="disease" post="characteristics need to identify urgently to perform in-vivo preclinical"/>
  <result pre="the risk population. To reduce the mortality and improve clinical" exact="disease" post="outcome; the research agenda should cover the investigation of"/>
  <result pre="2 Ad5- nCoV Genetically engineered vaccine with the replication-defective adenovirus" exact="type 5" post="as the vector to express SARS-CoV-2 spike protein CanSino"/>
  <result pre="coronavirus. Phase 2 Vaccine candidate is built upon CanSinoBIO's adenovirus-based" exact="viral" post="vector vaccine technology platform, applied to develop the globally"/>
  <result pre="Products/Sinopharm(ChiCTR2000034780) The body generates a diverse immune response against numerous" exact="viral" post="antigens after vaccination without any threat of actually being"/>
  <result pre="being infected as the virus is inactivated Phase 3 Inactive" exact="viral" post="vaccines are created by propagating viruses in cell culture"/>
  <result pre="College London(ISRCTN17072692) After vaccination into muscle, host cells produce the" exact="viral" post="spike protein and host's immune system produces antibodies in"/>
  <result pre="lentiviral vector expressing synthetic minigene based on domains of selected" exact="viral" post="proteins; administered with antigen-specific CTLs [131,140] 13 COVID-19/Aapc Artificial"/>
  <result pre="lentiviral vector expressing synthetic minigene based on domains of selected" exact="viral" post="proteins Shenzhen Geno-Immune Medical Institute(NCT04299724) The functionality is thought"/>
  <result pre="of proliferation by altering aAPCs with immune-modulatory genes and the" exact="viral" post="minigenes to represent SARS-CoV-2 antigens [131] [140] Table 2"/>
  <result pre="different types of nanoparticles used for the treatment of other" exact="viral" post="infections. Table 2 S.noS.no Nanoparticle Virus Mechanism of action"/>
  <result pre="products were ideal for biomedical applications and to fight against" exact="viral" post="infections [146] 2 siRNA-modified Polyethylenimine (PEI) encapsulated AgNPs Enterovirus"/>
  <result pre="were ideal for biomedical applications and to fight against viral" exact="infections" post="[146] 2 siRNA-modified Polyethylenimine (PEI) encapsulated AgNPs Enterovirus 71"/>
  <result pre="a prospective silver species with antiviral properties for treatment of" exact="viral" post="diseases. [147] 3 Glutathione-capped Ag2S nanoclusters (NCs) Porcine epidemic"/>
  <result pre="viral diseases. [147] 3 Glutathione-capped Ag2S nanoclusters (NCs) Porcine epidemic" exact="diarrhea" post="virus (PEDV) as a model of coronavirus Inhibits the"/>
  <result pre="(PEDV) as a model of coronavirus Inhibits the synthesis of" exact="viral" post="negative-strand RNA and viral budding The results suggest the"/>
  <result pre="of coronavirus Inhibits the synthesis of viral negative-strand RNA and" exact="viral" post="budding The results suggest the possibility to develop efficient"/>
  <result pre="outermost layer of PVPâ€&quot;PEG-coated silver nanorods (Adaâ€&quot;PVPâ€&quot;PEG silver nanorods) Human" exact="immunodeficiency" post="virus (HIV) Ada surface-modified silver nanorods promote HIV vaccine-triggered"/>
  <result pre="promote HIV vaccine-triggered cytotoxic lymphocytes to produce around eightfold stronger" exact="tumor" post="necrosis factor alpha in vivo Surface modifications of nanomaterials"/>
  <result pre="immunotherapy of HIV vaccine against HIV-infected cells. [149] 5 AgNP" exact="Respiratory" post="syncytial virus (RSV) NPs attach to viral glycoproteins, and"/>
  <result pre="[149] 5 AgNP Respiratory syncytial virus (RSV) NPs attach to" exact="viral" post="glycoproteins, and block entry into the host cell. AgNP-mediated"/>
  <result pre="the host cell. AgNP-mediated reduction in RSV replication, both in" exact="epithelial" post="cell lines and in experimentally infected BALB/c mice [150]"/>
  <result pre="virus â€&quot; Adjuvanticity efficacy [151] 7 Ammonium-terminated amphiphilic Janus dendrimers" exact="Hepatitis" post="C virus (HCV) Inhibit HCV replication by interacting with"/>
  <result pre="Hepatitis C virus (HCV) Inhibit HCV replication by interacting with" exact="viral" post="protein Nontoxic drug-loaded nanoaggregates inhibit HCV replication at low"/>
  <result pre="replication at low camptothecin concentration. [152] 8 Modified dendrimer NPs" exact="Venezuelan equine encephalitis" post="virus (VEEV) replicon RNAs Zika virus Activation of both"/>
  <result pre="low camptothecin concentration. [152] 8 Modified dendrimer NPs Venezuelan equine" exact="encephalitis" post="virus (VEEV) replicon RNAs Zika virus Activation of both"/>
  <result pre="replicon RNAs Zika virus Activation of both CD8+ T-cell and" exact="viral" post="E protein-specific IgG responses This approach can be used"/>
  <result pre="live virus. [153] 9 Glycodendrofullerenes Carbohydrate moieties (Mannose, Galactose) Pseudotyped" exact="viral" post="particles(Ebola virus glycoprotein) Blocking the dendritic cellâ€&quot;specificintercellular adhesion molecule-3â€&quot;grabbing"/>
  <result pre="Blocking the dendritic cellâ€&quot;specificintercellular adhesion molecule-3â€&quot;grabbing non-integrin receptor Inhibition of" exact="viral" post="attachmentleading to inhibited viral entry [154] 10 Gold (Au)/iron-oxide"/>
  <result pre="adhesion molecule-3â€&quot;grabbing non-integrin receptor Inhibition of viral attachmentleading to inhibited" exact="viral" post="entry [154] 10 Gold (Au)/iron-oxide magnetic NP-decorated Carbon nanotubes"/>
  <result pre="H1N1, norovirus DNA hybridization High sensitivity and selectivity detection of" exact="viral" post="DNA [155] 11 Monodispersed gold nanoparticles Herpes simplex virus"/>
  <result pre="DNA [155] 11 Monodispersed gold nanoparticles Herpes simplex virus Prevented" exact="viral" post="attachment and penetration into the Vero cells. Gold nanoparticles"/>
  <result pre="drug-associated toxicity. [157] 14 Amide functionalized alginate NPs HIV Inhibits" exact="viral" post="transcriptase Effective antiviral delivery [158] 15 Glycyrrhizic-acid-based carbon dots"/>
  <result pre="antiviral delivery [158] 15 Glycyrrhizic-acid-based carbon dots Porcine reproductive and" exact="respiratory" post="syndrome virus (PRRSV) Gly-CDs can inhibit PRRSV invasion and"/>
  <result pre="delivery [158] 15 Glycyrrhizic-acid-based carbon dots Porcine reproductive and respiratory" exact="syndrome" post="virus (PRRSV) Gly-CDs can inhibit PRRSV invasion and replication,"/>
  <result pre="animal models are to be developed to understand the enhanced" exact="disease" post="after vaccination. Therefore, a validated animal model should be"/>
  <result pre="preparedness. The only complication of COVID-19 is a type of" exact="pneumonia" post="called 2019 novel coronavirus-infected pneumonia (NCIP) in conjunction to"/>
  <result pre="COVID-19 is a type of pneumonia called 2019 novel coronavirus-infected" exact="pneumonia" post="(NCIP) in conjunction to ARDS, RNAaemia, acute cardiac injury,"/>
  <result pre="2019 novel coronavirus-infected pneumonia (NCIP) in conjunction to ARDS, RNAaemia," exact="acute" post="cardiac injury, and secondary infection associated with other types"/>
  <result pre="(NCIP) in conjunction to ARDS, RNAaemia, acute cardiac injury, and" exact="secondary" post="infection associated with other types of corona virus [142]."/>
  <result pre="in conjunction to ARDS, RNAaemia, acute cardiac injury, and secondary" exact="infection" post="associated with other types of corona virus [142]. Sekowski"/>
  <result pre="[142]. Sekowski et al reported the high chances of Posttraumatic" exact="Stress Disorder" post="(PTSD) in COVID-19 survivors based on previous research on"/>
  <result pre="Sekowski et al reported the high chances of Posttraumatic Stress" exact="Disorder" post="(PTSD) in COVID-19 survivors based on previous research on"/>
  <result pre="PTSD in epidemic survivors (e.g. SARS)[143]. PTSD is a serious" exact="mental disorder" post="that negatively affects functioning and social life by reliving"/>
  <result pre="affects functioning and social life by reliving the traumatic event," exact="emotional" post="numbness and increased arousal. Preliminary report by Bo et"/>
  <result pre="report by Bo et al indicated that almost all clinically" exact="stable" post="patients with COVID-19 in China experienced significant severity of"/>
  <result pre="the development of an antibody response will be protective from" exact="secondary" post="infection, according to WHO. Some countries suggested detection of"/>
  <result pre="more to win approval based on their ability to prevent" exact="disease" post="in population. Typically, HERD immunity isn't achieved in a"/>
  <result pre="disease in population. Typically, HERD immunity isn't achieved in a" exact="short" post="time like year or two and would take several"/>
  <result pre="impact. This study presents the current status of the deadly" exact="infectious" post="COVID-19 with special emphasis on the research agenda to"/>
  <result pre="covers all the areas such as ground work, epidemiology, immunology," exact="viral" post="therapeutics and vaccine. The challenges, knowledge gaps and the"/>
  <result pre="Pathol.153202042042110.1093/ajcp/aqaa02932053148 2GuoY.R.CaoQ.D.HongZ.S.TanY.Y.ChenS.D.JinH.J.Sen TanK.WangD.Y.YanY.The origin, transmission and clinical therapies on coronavirus" exact="disease" post="2019 (COVID-19) outbreak- an update on the statusMil. Med."/>
  <result pre="(COVID-19) outbreak- an update on the statusMil. Med. Res.7202011010.1186/s40779-020-00240-031928528 3HeF.DengY.LiW.Coronavirus" exact="disease" post="2019: what we know?J. Med. Virol.202020190210.1002/jmv.25766 4NicolaM.Oâ€™NeillN.SohrabiC.KhanM.AghaM.AghaR.Evidence based management"/>
  <result pre="Care Med.2012020P7P810.1164/rccm.2014P732004066 13WuZ.McGooganJ.M.Characteristics of and important lessons from the coronavirus" exact="disease" post="2019 (COVID-19) outbreak in China: summary of a report"/>
  <result pre="a report of 72314 cases from the Chinese Center for" exact="Disease" post="Control and PreventionJAMA - J. Am. Med. Assoc.32320201239124210.1001/jama.2020.2648 14RothanH.A.ByrareddyS.N.The"/>
  <result pre="J. Am. Med. Assoc.32320201239124210.1001/jama.2020.2648 14RothanH.A.ByrareddyS.N.The epidemiology and pathogenesis of coronavirus" exact="disease" post="(COVID-19) outbreakJ. Autoimmun.109202010243310.1016/j.jaut.2020.102433 15TuH.TuS.GaoS.ShaoA.ShengJ.Current epidemiological and clinical features of"/>
  <result pre="(H1N1) virusScience (80-)326200972973310.1126/science.1177373 26KucharskiA.J.AlthausC.L.The role of superspreading in middle east" exact="respiratory" post="syndrome coronavirus (MERS-CoV) transmissionEurosurveillance.202015141810.2807/1560-7917.ES2015.20.25.2116726132768 27Coronavirus, (n.d). https://www.who.int/health-topics/coronavirus#tab=tab_2 (accessed June"/>
  <result pre="virusScience (80-)326200972973310.1126/science.1177373 26KucharskiA.J.AlthausC.L.The role of superspreading in middle east respiratory" exact="syndrome" post="coronavirus (MERS-CoV) transmissionEurosurveillance.202015141810.2807/1560-7917.ES2015.20.25.2116726132768 27Coronavirus, (n.d). https://www.who.int/health-topics/coronavirus#tab=tab_2 (accessed June 12,"/>
  <result pre="(MERS-CoV) transmissionEurosurveillance.202015141810.2807/1560-7917.ES2015.20.25.2116726132768 27Coronavirus, (n.d). https://www.who.int/health-topics/coronavirus#tab=tab_2 (accessed June 12, 2020). 28HarapanH.ItohN.YufikaA.WinardiW.KeamS.TeH.MegawatiD.HayatiZ.WagnerA.L.MudatsirM.Coronavirus" exact="disease" post="2019 (COVID-19): A literature reviewJ. Infect. Public Health.13202066767310.1016/j.jiph.2020.03.01932340833 29LiY.ZhangZ.YangL.XinS.CaoP.LuJ.The"/>
  <result pre="the 2019-nCoV spike in the prefusion conformationScience (80-)36720201260126310.1126/science.abb2507 35MooreJ.B.JuneC.H.Cytokine release" exact="syndrome" post="in severe COVID-19Science (80-)368202047347410.1126/science.abb8925 36YeQ.WangB.MaoJ.The pathogenesis and treatment of"/>
  <result pre="COVID-19J. Inf. Secur.80202060761310.1016/j.jinf.2020.03.037 37WanS.YiQ.FanS.LvJ.ZhangX.GuoL.LangC.XiaoQ.XiaoK.YiZ.QiangM.XiangJ.ZhangB.ChenY.Characteristics of lymphocyte subsets and cytokines in" exact="peripheral" post="blood of 123 hospitalized patients with 2019 novel coronavirus"/>
  <result pre="peripheral blood of 123 hospitalized patients with 2019 novel coronavirus" exact="pneumonia" post="(NCP)MedRxiv.202010.1101/2020.02.10.200218322020.02.10.20021832 38(No Title), (n.d.). https://www.mohfw.gov.in/pdf/GuidelinesonClinicalManagementofCOVID1912020.pdf (accessed June 15, 2020)."/>
  <result pre="in comparison with ribavirin, Favipiravir, Oseltamivir and Umifenovir in coronavirus" exact="disease" post="2019 (COVID-19) pandemicSSRN Electron. J.202010.2139/ssrn.3569866 45VellingiriB.JayaramayyaK.IyerM.NarayanasamyA.GovindasamyV.GiridharanB.GanesanS.VenugopalA.VenkatesanD.GanesanH.RajagopalanK.RahmanP.K.S.M.ChoS.G.KumarN.S.SubramaniamM.D.COVID-19: a promising cure"/>
  <result pre="Electron. J.202010.2139/ssrn.3569866 45VellingiriB.JayaramayyaK.IyerM.NarayanasamyA.GovindasamyV.GiridharanB.GanesanS.VenugopalA.VenkatesanD.GanesanH.RajagopalanK.RahmanP.K.S.M.ChoS.G.KumarN.S.SubramaniamM.D.COVID-19: a promising cure for the global panicSci." exact="Total" post="Environ.725202013827710.1016/j.scitotenv.2020.138277 46Translation: Management of Coronavirus Disease 2019 (COVID-19): experience"/>
  <result pre="for the global panicSci. Total Environ.725202013827710.1016/j.scitotenv.2020.138277 46Translation: Management of Coronavirus" exact="Disease" post="2019 (COVID-19): experience in Zhejiang Province, China, (n.d). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227201/"/>
  <result pre="announces development of anti-GM-CSF monoclonal antibody to prevent and treat" exact="acute" post="respiratory distress syndrome (ARDS) in patients with COVID-19|Roivant Sciences,"/>
  <result pre="development of anti-GM-CSF monoclonal antibody to prevent and treat acute" exact="respiratory" post="distress syndrome (ARDS) in patients with COVID-19|Roivant Sciences, (n.d)."/>
  <result pre="anti-GM-CSF monoclonal antibody to prevent and treat acute respiratory distress" exact="syndrome" post="(ARDS) in patients with COVID-19|Roivant Sciences, (n.d). https://roivant.com/roivant-announces-development-of-anti-gm-csf-monoclonal-antibody-to-prevent-and-treat-acute-respiratory-distress-syndrome-ards-in-patients-with-covid-19.html (accessed"/>
  <result pre="Drug Deliv.122015869710.2174/156720181166614091811452825233122 60DuncanJ.E.WhitsettJ.A.HorowitzA.D.Pulmonary surfactant inhibits cationic liposome-mediated gene delivery to" exact="respiratory" post="epithelial cells in vitroHum. Gene Ther.8199743143810.1089/hum.1997.8.4-4319054518 61El-SherbinyI.M.El-BazN.M.YacoubM.H.Inhaled nano- and"/>
  <result pre="Deliv.122015869710.2174/156720181166614091811452825233122 60DuncanJ.E.WhitsettJ.A.HorowitzA.D.Pulmonary surfactant inhibits cationic liposome-mediated gene delivery to respiratory" exact="epithelial" post="cells in vitroHum. Gene Ther.8199743143810.1089/hum.1997.8.4-4319054518 61El-SherbinyI.M.El-BazN.M.YacoubM.H.Inhaled nano- and microparticles"/>
  <result pre="drug deliveryGlob. Cardiol. Sci. Pract.20152015210.5339/gcsp.2015.226779496 62VelkovT.Abdul RahimN.ZhouQ.T.ChanH.K.LiJ.Inhaled anti-infective chemotherapy for" exact="respiratory" post="tract infections: successes, challenges and the road aheadAdv. Drug"/>
  <result pre="potential antiviral agentsMolecules1620118894891810.3390/molecules1610889422024958 68GharseS.FiegelJ.Large porous hollow particles: lightweight champions of" exact="pulmonary" post="drug deliveryCurr. Pharm. Des.2220162463246910.2174/138161282266616012814535626818876 69Garcia-ContrerasL.FiegelJ.TelkoM.J.ElbertK.HawiA.ThomasM.VerBerkmoesJ.GermishuizenW.A.FourieP.B.HickeyA.J.EdwardsD.A.Inhaled large porous particles of"/>
  <result pre="Des.2220162463246910.2174/138161282266616012814535626818876 69Garcia-ContrerasL.FiegelJ.TelkoM.J.ElbertK.HawiA.ThomasM.VerBerkmoesJ.GermishuizenW.A.FourieP.B.HickeyA.J.EdwardsD.A.Inhaled large porous particles of capreomycin for treatment of" exact="tuberculosis" post="in a Guinea pig modelAntimicrob. Agents Chemother.5120072830283610.1128/AAC.01164-0617517845 70Ben-JebriaA.EskewM.L.EdwardsD.A.Inhalation system"/>
  <result pre="in a Guinea pig modelAntimicrob. Agents Chemother.5120072830283610.1128/AAC.01164-0617517845 70Ben-JebriaA.EskewM.L.EdwardsD.A.Inhalation system for" exact="pulmonary" post="aerosol drug delivery in rodents using large porous particlesAerosol"/>
  <result pre="controlled release inhalation therapyAAPS J.11200977177810.1208/s12248-009-9148-619908147 74KerryR.G.MalikS.ReddaY.T.SahooS.PatraJ.K.MajhiS.Nano-based approach to combat emerging" exact="viral" post="(NIPAH virus) infectionNanomedicine Nanotechnology, Biol. Med.18201919622010.1016/j.nano.2019.03.004 75PoonC.PatelA.A.Organic and inorganic"/>
  <result pre="Biol. Med.18201919622010.1016/j.nano.2019.03.004 75PoonC.PatelA.A.Organic and inorganic nanoparticle vaccines for prevention of" exact="infectious" post="diseasesNano Express1202001200110.1088/2632-959X/AB8075 76El-MohamadyR.S.GhattasT.A.ZawrahM.F.Abd El-HafeizY.G.M.Inhibitory effect of silver nanoparticles on"/>
  <result pre="Immunol41201427929310.1016/j.fsi.2014.09.01425240976 82YangX.X.LiC.M.LiY.F.WangJ.HuangC.Z.Synergistic antiviral effect of curcumin functionalized graphene oxide against" exact="respiratory" post="syncytial virus infectionNanoscale92017160861609210.1039/c7nr06520e29034936 83LuczkowiakJ.MuÃ±ozA.SÃ¡nchez-NavarroM.Ribeiro-VianaR.GinieisA.IllescasB.M.MartÃ­nN.DelgadoR.RojoJ.Glycofullerenes inhibit viral infectionBiomacromolecules14201343143710.1021/bm301665823281578 84MuÃ±ozA.IllescasB.M.LuczkowiakJ.LasalaF.Ribeiro-VianaR.RojoJ.DelgadoR.MartÃ­nN.Antiviral activity"/>
  <result pre="functionalized graphene oxide against respiratory syncytial virus infectionNanoscale92017160861609210.1039/c7nr06520e29034936 83LuczkowiakJ.MuÃ±ozA.SÃ¡nchez-NavarroM.Ribeiro-VianaR.GinieisA.IllescasB.M.MartÃ­nN.DelgadoR.RojoJ.Glycofullerenes inhibit" exact="viral" post="infectionBiomacromolecules14201343143710.1021/bm301665823281578 84MuÃ±ozA.IllescasB.M.LuczkowiakJ.LasalaF.Ribeiro-VianaR.RojoJ.DelgadoR.MartÃ­nN.Antiviral activity of self-assembled glycodendro[60]fullerene monoadductsJ. Mater. Chem."/>
  <result pre="quantum dotsArtif. Cells, Nanomedicine Biotechnol.44201675876810.3109/21691401.2015.1052468 93XuG.MahajanS.RoyI.YongK.T.Theranostic quantum dots for crossing" exact="blood-brain barrier" post="in vitro and providing therapy of HIV-associated encephalopathyFront. Pharmacol.201310.3389/fphar.2013.001404"/>
  <result pre="in drug delivery and regenerative medicineCurr. Pharm. Des.222016110.2174/1381612822666161021104239 100SonajeK.ChuangE.Y.LinK.J.YenT.C.SuF.Y.TsengM.T.SungH.W.Opening of" exact="epithelial" post="tight junctions and enhancement of paracellular permeation by chitosan:"/>
  <result pre="project, (n.d). doi:10.7150/thno.46691. 103The rise and fall of hyaluronan in" exact="respiratory" post="diseases, (n.d). https://www.hindawi.com/journals/ijcb/2015/712507/ (accessed June 14, 2020). 104MattheolabakisG.MilaneL.SinghA.AmijiM.M.Hyaluronic acid"/>
  <result pre="(accessed June 14, 2020). 104MattheolabakisG.MilaneL.SinghA.AmijiM.M.Hyaluronic acid targeting of CD44 for" exact="cancer" post="therapy: from receptor biology to nanomedicineJ. Drug Target.23201560561810.3109/1061186X.2015.105207226453158 105SepÃºlveda-CrespoD.CeÃ±a-DÃ­ezR.JimÃ©nezJ.L.Ã�ngeles"/>
  <result pre="receptor biology to nanomedicineJ. Drug Target.23201560561810.3109/1061186X.2015.105207226453158 105SepÃºlveda-CrespoD.CeÃ±a-DÃ­ezR.JimÃ©nezJ.L.Ã�ngeles MuÃ±oz-FernÃ¡ndezM.Mechanistic studies of" exact="viral" post="entry: an overview of Dendrimer-based Microbicides as entry inhibitors"/>
  <result pre="Nanomedicine, Biotechnol.4420161626163410.3109/21691401.2015.1129625 108JoshyK.S.SnigdhaS.AnneG.NandakumarK.LalyP.SabuA.T.Poly (vinyl pyrrolidone)-lipid based hybrid nanoparticles for anti" exact="viral" post="drug deliveryChem. Phys. Lipids2102018828910.1016/j.chemphyslip.2017.11.00329129570 109(No Title), (n.d). http://www.nanoviricides.com/Antiviral_Therapeutics_technologies_markets_and_companies_January_2008.pdf (accessed"/>
  <result pre="herd immunity and convalescent plasma transfer therapyJ. Med. Virol.202010.1002/jmv.25870 113ChanJ.F.W.YuanS.KokK.H.ToK.K.W.ChuH.A" exact="familial" post="cluster of pneumonia associated with the 2019 novel coronavirus"/>
  <result pre="convalescent plasma transfer therapyJ. Med. Virol.202010.1002/jmv.25870 113ChanJ.F.W.YuanS.KokK.H.ToK.K.W.ChuH.A familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating person-to-person transmission:"/>
  <result pre="study of a family clusterLancet395202051452310.1016/S0140-6736(20)30154-931986261 114ImaiN.DorigattiI.CoriA.DonnellyC.RileyS.FergusonN.M.Report 2: Estimating the Potential" exact="Total" post="Number of Novel Coronavirus (2019-nCoV) Cases in Wuhan City,"/>
  <result pre="128Number Type of Product-Treatment FDA-Approved Indications Clinical Trials for Other" exact="Diseases" post="Developer/Researcher Current Stage of Development Funding Sources Clinical Trials"/>
  <result pre="Roadmap: 2019 Novel Coronavirus2020 142Arshad AliS.BalochM.AhmedN.Arshad AliA.IqbalA.The outbreak of coronavirus" exact="disease" post="2019 (COVID-19)â€&quot;an emerging global health threatJ. Infect. Public Health13202064464610.1016/j.jiph.2020.02.03332199792"/>
  <result pre="M. Gambin, K. Hansen, P. Holas, Risk of Developing Posttraumatic" exact="Stress Disorder" post="in COVID-19 Survivors: What Should Mental Health Specialists Prepare"/>
  <result pre="Gambin, K. Hansen, P. Holas, Risk of Developing Posttraumatic Stress" exact="Disorder" post="in COVID-19 Survivors: What Should Mental Health Specialists Prepare"/>
  <result pre="symptoms and attitude toward crisis mental health services among clinically" exact="stable" post="patients with COVID-19 in ChinaPsychol. Med.202010.1017/S0033291720000999 145A coronavirus vaccine"/>
  <result pre="Adv.720171453146310.1039/c6ra26472g 148DuT.LiangJ.DongN.LuJ.FuY.FangL.XiaoS.HanH.Glutathione-capped Ag2S Nanoclusters inhibit coronavirus proliferation through blockage of" exact="viral" post="RNA synthesis and buddingACS Appl. Mater. Interfaces1020184369437810.1021/acsami.7b1381129337529 149LiW.BalachandranY.L.HaoY.HaoX.LiR.NanZ.ZhangH.ShaoY.LiuY.Amantadine surface-modified"/>
  <result pre="of G2 citric acid-based Dendrimer as an adjuvant in veterinary" exact="rabies" post="vaccineViral Immunol.312018475410.1089/vim.2017.002429328884 152LancelotA.ClaverÃ­a-GimenoR.VelÃ¡zquez-CampoyA.AbianO.SerranoJ.L.SierraT.Nanostructures based on ammonium-terminated amphiphilic Janus dendrimers"/>
  <result pre="platformBiosens. Bioelectron.102201842543110.1016/j.bios.2017.11.05229175218 156HalderA.DasS.OjhaD.ChattopadhyayD.MukherjeeA.Highly monodispersed gold nanoparticles synthesis and inhibition of" exact="herpes" post="simplex virus infectionsMater. Sci. Eng. C.89201841342110.1016/j.msec.2018.04.005 157KumarP.LakshmiY.S.KondapiA.K.Triple drug combination"/>
 </snippets>
</snippetsTree>
